Returns for the stock were -7% in 2021, 32% in 2022, 41% in 2023, and -1% in 2024. Looking forward, VRTX stock may continue to see higher levels. At its current levels, VRTX stock is trading at 11 ...

VERTEX PHARMACEUTICALS INC (VRTX) is a large-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the ...

In the latest market close, Vertex Pharmaceuticals (VRTX) reached $409.56, with a -0.62% movement compared to the previous day. This change was narrower than the S&P 500's 1.54% loss on the day.

Vertex Pharmaceuticals (VRTX) stock is rising after receiving approval by the Food and Drug Administration (FDA) over its new non-opioid pain management drug, Journavx. Lastly, oil giants Exxon ...